| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Bleeding with direct oral anticoagulants vs warfarin: clinical experience
|
Eikelboom, John
|
|
2016
|
|
11S |
p. 3-8
6 p.
|
artikel
|
| 2 |
Discontinuation and management of direct-acting anticoagulants for emergency procedures
|
Levy, Jerrold H.
|
|
2016
|
|
11S |
p. 14-18
5 p.
|
artikel
|
| 3 |
Editorial Board
|
|
|
2016
|
|
11S |
p. A1-
1 p.
|
artikel
|
| 4 |
Evidence supporting idarucizumab for the reversal of dabigatran
|
Pollack Jr, Charles V.
|
|
2016
|
|
11S |
p. 33-38
6 p.
|
artikel
|
| 5 |
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols
|
Huisman, Menno V.
|
|
2016
|
|
11S |
p. 46-51
6 p.
|
artikel
|
| 6 |
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects
|
Reilly, Paul A.
|
|
2016
|
|
11S |
p. 26-32
7 p.
|
artikel
|
| 7 |
Information for Authors
|
|
|
2016
|
|
11S |
p. A3-A4
nvt p.
|
artikel
|
| 8 |
Introduction to direct oral anticoagulants and rationale for specific reversal agents
|
Pollack Jr, Charles V.
|
|
2016
|
|
11S |
p. 1-2
2 p.
|
artikel
|
| 9 |
Preclinical and clinical data for factor Xa and “universal” reversal agents
|
Milling Jr, Truman J.
|
|
2016
|
|
11S |
p. 39-45
7 p.
|
artikel
|
| 10 |
Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed
|
Milling Jr, Truman J.
|
|
2016
|
|
11S |
p. 19-25
7 p.
|
artikel
|
| 11 |
Safety of direct oral anticoagulants: insights from postmarketing studies
|
Villines, Todd C.
|
|
2016
|
|
11S |
p. 9-13
5 p.
|
artikel
|
| 12 |
Table of Contents
|
|
|
2016
|
|
11S |
p. A2-
1 p.
|
artikel
|
Tijdschrift beschrijving